NCIC CLINICAL TRIALS GROUP

RADIATION FORUM

MEETING AGENDA

EATON CHELSEA HOTEL, TORONTO, ON

ROOM: SEYMOUR

FRIDAY, MAY 2ND, 2014 – 8:30 AM – 12:00 PM

CHAIR: M. MCKENZIE

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:

− To understand and address, through clinical and translational research, the disease burden associated with solid tumours and haematological malignancies treated with radiotherapy in Canada.
− To review recent developments in the understanding of molecular biology of cancers treated with radiotherapy.
− To update, review, and discuss recent results of clinical studies involving radiotherapy conducted by the NCIC Clinical Trials Group or national/international collaborators.
− To provide mentoring opportunities for investigators new to clinical trial research.
− To understand and apply new clinical trial methodologies in the field of clinical research.

8:30 am Welcome
M. McKenzie

NCIC CTG led trials: Ongoing

8:35 am Dexamethasone vs. placebo in the prophylaxis of radiation-induced pain flare following palliative radiotherapy for bone met. NCIC CTG SC.23
R. Wong

8:45 am HDR brachytherapy in intermediate risk CaP. NCIC CTG PR.15
E. Vigneault

NCIC CTG Intergroup studies: Ongoing

8:55 am Radiation doses and fractionation schedules for DCIS of the breast. NCIC CTG MA.33
I. Olivotto

9:05 am Preoperative Chemoradiotherapy vs. Preoperative Chemotherapy for Resectable Gastric Cancer. NCIC CTG GA.1
J. Ringash / R. Wong

continued on next page ...
Updates in NCIC CTG approved studies:

9:15 am  Phase III regional radiotherapy in early breast cancer treated by breast-conserving surgery and sentinel lymph node biopsy. NCIC CTG MA.35  M. McKenzie

Updates on previous discussed proposals

9:25 am  Randomized study of single 8 Gy versus BSC for symptomatic primary or metastatic liver cancer.  L. Dawson

9:35 am  Adjuvant radiotherapy in bladder cancer.  L. Eapen

9:45 am  Stereotactic RT for oligo-progression of metastatic kidney cancer patients on 1st line targeted therapy: Phase II  P. Cheung

New Study proposals

9:55 am  Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases. (Alliance 221208)  C. Chung

10:15 am  Coffee Break

10:35 am  Randomized phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localized, prostate cancer. ENZARAD (ANZUP)  T. Niazi

10:55 am  Imagining a Canadian Randomized Controlled Trial for Brain Metastases.  A. Nichol

11:15 am  Head and Neck proposals.  B. O’Sullivan / J. Waldron

11:45 am  Activities of the ROQAC.  A. Nichol/C. Field

12:00 pm  Meeting adjourned.